Crossmark

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)

Crossref DOI link: https://doi.org/10.1016/j.phrs.2021.105422

Published Print: 2021-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Roskoski, Robert Jr. https://orcid.org/0000-0001-9861-4139
License Information

Text and Data Mining valid from 2021-03-01

Text and Data Mining valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01
More Information

This article is maintained by: Elsevier

Article Title: Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)

Journal Title: Pharmacological Research

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.phrs.2021.105422

Content Type: article

Copyright: © 2021 Elsevier Ltd. All rights reserved.